The demographic characteristics and prognosis of acute myeloid leukemia with t(3;3)/inv(3) in the united states: a SEER-based study

Abstract

Abstract Acute myeloid leukemia (AML) with t(3;3) (q21; q26.2) or inv(3) (q21; q26.2) is a rare subtype of acute myeloid leukemia with a poor prognosis. Research on the demographic characteristics and clinical outcomes of AML patients with t(3;3) (q21; q26.2) or inv(3) (q21; q26.2) is limited. All AML patients diagnosed with t(3;3) (q21; q26.2) or inv(3) (q21; q26.2) between 2000 and 2021 from SEER (Surveillance, Epidemiology, and End Results Program) database were included in this study. Survival analysis was performed using the Kaplan–Meier method. The log-rank test was used to analyze the significance of differences between overall survival (OS) and cancer-specific survival (CSS). Due to being a retrospective study, the limited amount of baseline characteristics available, and the missing information on treatments and recurrence, the provided dataset is not exactly representative for the US population. The median age of the total 90 AML patients with t(3;3) (q21; q26.2) or inv(3) (q21; q26.2) was 65(49–74) years old. Among them, 57.78% were married and non-Hispanic whites accounted for 74.44%. 84.44% of the patients received chemotherapy. The median OS was 8 months, and the median CSS was 10 months. The 5-year survival rate for OS was 15.29% (95%CI:7.98-24.78%), and 20.05% (95%CI:10.69–31.51%) for CSS. The OS and CSS of patients above 60 years were inferior to those of patients under 60 years. Single (never-married) patients had better OS and CSS than those with other marital status. Age and marital status at diagnosis were independent influencing factors for OS and CSS based on the multivariate COX regression analysis. AML with t(3;3) (q21; q26.2) or inv(3) (q21; q26.2) mostly occurs in adults and has poor clinical outcomes with worse OS and CSS, especially in the elderly.